» Articles » PMID: 38004266

Oral Bioavailability and Pharmacokinetics of Sildenafil Orally Disintegrating Tablets Under Various Gastric PH Levels Following Administration of Omeprazole in Rats

Overview
Journal Life (Basel)
Specialty Biology
Date 2023 Nov 25
PMID 38004266
Authors
Affiliations
Soon will be listed here.
Abstract

Sildenafil citrate, an oral drug used to treat erectile dysfunction, has low water solubility and oral bioavailability. The solubility is greatly influenced by the pH, changing from 37.25 mg/mL to 0.22 mg/mL with a change in pH from 1.2 to 8.0. This indicates that the absorption may decrease in patients who use drugs, such as proton pump inhibitors (PPIs), for gastroesophageal reflux disease. To improve the absorption of sildenafil citrate at various gastric pH levels, a sildenafil citrate orally disintegrating tablet (ODT), which has a rapid disintegration feature, was produced by a 3D printing technique. Our study investigated the pharmacokinetic parameters of the sildenafil citrate ODT in rats after oral administration and compared the absorption of the sildenafil citrate ODT and sildenafil citrate commercial tablet (RLD), with and without PPI treatment. The LC/MS/MS analysis of the plasma sildenafil concentration revealed that the area under curve from time 0 to infinity (AUC) of sildenafil in the sildenafil citrate ODT group was significantly higher than in the sildenafil citrate RLD group whether it was in combination with the PPI or not (274.8% and 144%, respectively; < 0.05). The relative systemic bioavailability of sildenafil citrate RLD significantly decreased with the PPI, but that of sildenafil citrate ODT was not affected by the PPI. These results indicate that the relative systemic bioavailability of sildenafil citrate ODT was increased when it was prepared using the 3D printing technique and the absorption of this formulation was not affected by the PPI.

References
1.
Kim T, Shin S, Jeong S, Lee J, Shin B . Physiologically Relevant In Vitro-In Vivo Correlation (IVIVC) Approach for Sildenafil with Site-Dependent Dissolution. Pharmaceutics. 2019; 11(6). PMC: 6631943. DOI: 10.3390/pharmaceutics11060251. View

2.
Fink H, Mac Donald R, Rutks I, Nelson D, Wilt T . Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med. 2002; 162(12):1349-60. DOI: 10.1001/archinte.162.12.1349. View

3.
Kim H, Conklin J, Park H . The effect of sildenafil on segmental oesophageal motility and gastro-oesophageal reflux. Aliment Pharmacol Ther. 2006; 24(7):1029-36. DOI: 10.1111/j.1365-2036.2006.03091.x. View

4.
Shi S, Klotz U . Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008; 64(10):935-51. DOI: 10.1007/s00228-008-0538-y. View

5.
Miranda C, Perez-Rodriguez Z, Hernandez-Armengol R, Quinones-Garcia Y, Betancourt-Puron T, Cabrera-Perez M . Biowaiver or Bioequivalence: Ambiguity in Sildenafil Citrate BCS Classification. AAPS PharmSciTech. 2018; 19(4):1693-1698. DOI: 10.1208/s12249-018-0982-7. View